Investment Advisor, PN Vijay is of the view that if one wants to put some weightage in pharma, Ranbaxy Laboratories would be a very good bet.

Vijay told CNBC-TV18, "Ranbaxy seems to be getting out of its problem one by one and turning positive. They went global and that backfired, they are putting the people back and its been a good performer, so if one wants to put some weightage in pharma, this portfolio which is the under owned sector right now and Ranbaxy would be a very good bet, one can’t loss and one could get a steady gain out of the stock."

He further added, "Mphasis is been doing many interesting things they bought over and they buy etc. The latest deal I think make sense HP as a war chest EDF is a fairly troubled company, given the problems of the parent. So I think that the deal may go through in which case who knows HP have such a huge operations in India that they may pay a fancy price for Mphasis. So speculators are making some right guesses here but the fundamentals of the BPO company do not warrant this right."

Disclosure: It is safe to assume that analyst and his clients may have an interest in the stocks/sectors discussed.